Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental combo targets tough liver cancer

NCT ID NCT06519721

Disease control Sponsor: RenJi Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early trial tests whether combining the drug lenvatinib with a new experimental drug, VIC-1911, is safe and can shrink tumors in people with advanced liver cancer. Only 12 participants will be enrolled, and the study is open-label, meaning everyone gets the combination. The main goal is to see how many patients respond, but it is too early to know if this will become a standard treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
lenvatinib combined with VIC-1911
What this could lead to
If it works, this could point toward a new combination treatment for advanced liver cancer that may shrink tumors or slow disease progression.
What could go wrong
This is a very early, small trial (12 people) with no control group. The combination may cause side effects or fail to show benefit. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

12 people

The number who actually took part.

Started

Aug 2024

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Gender unrestricted, age 18-75 years; * HCC conforms to AASLD or EASL clinical diagnostic standards; * HCC Barcelona Clinic Liver Cancer (BCLC) staging is C, with at least one measurable tumor in the liver (longest diameter ≥1cm); * Liver function Child-Pugh Class A or Class B with a score of 7; * ECOG score of 0-1; * Platelet count ≥60×10\^9/L, PT time prolongation ≤6 seconds. Exclusion Criteria: * Irreversible coagulation dysfunction, with obvious bleeding tendency; * Patients who need long-term anticoagulation or antiplatelet treatment and cannot stop medication; * Patients with unstable or active ulcers, gastrointestinal bleeding; * Patients with untreated heart disease or poorly controlled hypertension as judged by the researcher; * Severe dysfunction of important organs, such as severe cardiopulmonary dysfunction; * Patients with hepatic encephalopathy or refractory ascites requiring treatment; * Human Immunodeficiency Virus (HIV) infection; * Active Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) infection (activity defined as viral load \> 20000 IU/mL), or HBV, HCV positive patients who refuse to accept standardized antiviral treatment; * Inability to swallow oral medication. * Gastrointestinal diseases that may affect the absorption or tolerance of the study medication. * History of corneal epithelial cysts or other causes of blurred vision, or medical abnormalities found in ophthalmic screening. * Known allergy to VIC-1911 or its components. * Within 4 weeks before the study, radiotherapy or interventional therapy for the disease under study was performed; * Other concurrent antitumor treatments; * The researcher assesses that the patient cannot or is unwilling to comply with the requirements of the study protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma

Contacts and locations

Locations

  • Deparment of Liver Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University

    Shanghai, 200127, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.